140 related articles for article (PubMed ID: 38531056)
1. Neutrophil functions in patients with neutropenia due to glycogen storage disease type 1b treated with empagliflozin.
Kaczor M; Malicki S; Folkert J; Dobosz E; Bryzek D; Chruscicka-Smaga B; Greczan M; Wesół-Kucharska D; Piątosa B; Samborowska E; Madzio J; Książyk J; Ehmke Vel Emczyńska E; Hajdacka M; Potempa J; Młynarski W; Rokicki D; Veillard F
Blood Adv; 2024 Jun; 8(11):2790-2802. PubMed ID: 38531056
[TBL] [Abstract][Full Text] [Related]
2. Empagliflozin for treating neutropenia and neutrophil dysfunction in 21 infants with glycogen storage disease 1b.
Grünert SC; Gautschi M; Baker J; Boyer M; Burlina A; Casswall T; Corpeleijn W; Çıki K; Cotter M; Crushell E; Derks TGJ; Haas D; Kilavuz S; Kingma SDK; Korman SH; Kozek A; de Laet C; Mundy H; Nassogne MC; Quintero V; Rossi A; Spenger J; Spiegel R; Stephenne X; Stojkov D; Tal G; Veiga-da Cunha M; Wortmann SB
Mol Genet Metab; 2024 Jun; 142(2):108486. PubMed ID: 38733639
[TBL] [Abstract][Full Text] [Related]
3. Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor.
Wortmann SB; Van Hove JLK; Derks TGJ; Chevalier N; Knight V; Koller A; Oussoren E; Mayr JA; van Spronsen FJ; Lagler FB; Gaughan S; Van Schaftingen E; Veiga-da-Cunha M
Blood; 2020 Aug; 136(9):1033-1043. PubMed ID: 32294159
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo effects of granulocyte colony-stimulating factor on neutrophils in glycogen storage disease type 1B: granulocyte colony-stimulating factor therapy corrects the neutropenia and the defects in respiratory burst activity and Ca2+ mobilization.
McCawley LJ; Korchak HM; Douglas SD; Campbell DE; Thornton PS; Stanley CA; Baker L; Kilpatrick L
Pediatr Res; 1994 Jan; 35(1):84-90. PubMed ID: 7510873
[TBL] [Abstract][Full Text] [Related]
5. Treatment recommendations for glycogen storage disease type IB- associated neutropenia and neutrophil dysfunction with empagliflozin: Consensus from an international workshop.
Grünert SC; Derks TGJ; Mundy H; Dalton RN; Donadieu J; Hofbauer P; Jones N; Uçar SK; LaFreniere J; Contreras EL; Pendyal S; Rossi A; Schneider B; Spiegel R; Stepien KM; Wesol-Kucharska D; Veiga-da-Cunha M; Wortmann SB
Mol Genet Metab; 2024 Mar; 141(3):108144. PubMed ID: 38277989
[TBL] [Abstract][Full Text] [Related]
6. Crohn disease-like enterocolitis remission after empagliflozin treatment in a child with glycogen storage disease type Ib: a case report.
Rossi A; Miele E; Fecarotta S; Veiga-da-Cunha M; Martinelli M; Mollica C; D'Armiento M; Mozzillo E; Strisciuglio P; Derks TGJ; Staiano A; Parenti G
Ital J Pediatr; 2021 Jul; 47(1):149. PubMed ID: 34215305
[TBL] [Abstract][Full Text] [Related]
7. Successful use of empagliflozin to treat neutropenia in two G6PC3-deficient children: Impact of a mutation in SGLT5.
Boulanger C; Stephenne X; Diederich J; Mounkoro P; Chevalier N; Ferster A; Van Schaftingen E; Veiga-da-Cunha M
J Inherit Metab Dis; 2022 Jul; 45(4):759-768. PubMed ID: 35506446
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human granulocyte colony-stimulating factor therapy for patients with neutropenia and/or neutrophil dysfunction secondary to glycogen storage disease type 1b.
Calderwood S; Kilpatrick L; Douglas SD; Freedman M; Smith-Whitley K; Rolland M; Kurtzberg J
Blood; 2001 Jan; 97(2):376-82. PubMed ID: 11154211
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of empagliflozin in glycogen storage disease type Ib: Data from an international questionnaire.
Grünert SC; Derks TGJ; Adrian K; Al-Thihli K; Ballhausen D; Bidiuk J; Bordugo A; Boyer M; Bratkovic D; Brunner-Krainz M; Burlina A; Chakrapani A; Corpeleijn W; Cozens A; Dawson C; Dhamko H; Milosevic MD; Eiroa H; Finezilber Y; Moura de Souza CF; Garcia-Jiménez MC; Gasperini S; Haas D; Häberle J; Halligan R; Fung LH; Hörbe-Blindt A; Horka LM; Huemer M; Uçar SK; Kecman B; Kilavuz S; Kriván G; Lindner M; Lüsebrink N; Makrilakis K; Mei-Kwun Kwok A; Maier EM; Maiorana A; McCandless SE; Mitchell JJ; Mizumoto H; Mundy H; Ochoa C; Pierce K; Fraile PQ; Regier D; Rossi A; Santer R; Schuman HC; Sobieraj P; Spenger J; Spiegel R; Stepien KM; Tal G; Tanšek MZ; Torkar AD; Tchan M; Thyagu S; Schrier Vergano SA; Vucko E; Weinhold N; Zsidegh P; Wortmann SB
Genet Med; 2022 Aug; 24(8):1781-1788. PubMed ID: 35503103
[TBL] [Abstract][Full Text] [Related]
10. Favorable outcome of empagliflozin treatment in two pediatric glycogen storage disease type 1b patients.
Hexner-Erlichman Z; Veiga-da-Cunha M; Zehavi Y; Vadasz Z; Sabag AD; Tatour S; Spiegel R
Front Pediatr; 2022; 10():1071464. PubMed ID: 36507137
[TBL] [Abstract][Full Text] [Related]
11. Improved inflammatory bowel disease, wound healing and normal oxidative burst under treatment with empagliflozin in glycogen storage disease type Ib.
Grünert SC; Elling R; Maag B; Wortmann SB; Derks TGJ; Hannibal L; Schumann A; Rosenbaum-Fabian S; Spiekerkoetter U
Orphanet J Rare Dis; 2020 Aug; 15(1):218. PubMed ID: 32838757
[TBL] [Abstract][Full Text] [Related]
12. Improvement of neutropenia and neutrophil dysfunction by granulocyte colony-stimulating factor in a patient with glycogen storage disease type Ib.
Ishiguro A; Nakahata T; Shimbo T; Amano Y; Yasui K; Koike K; Komiyama A
Eur J Pediatr; 1993 Jan; 152(1):18-20. PubMed ID: 7680314
[TBL] [Abstract][Full Text] [Related]
13. Amelioration of neutrophil membrane function underlies granulocyte-colony stimulating factor action in glycogen storage disease 1b.
Lesma E; Riva E; Giovannini M; Di Giulio AM; Gorio A
Int J Immunopathol Pharmacol; 2005; 18(2):297-307. PubMed ID: 15888252
[TBL] [Abstract][Full Text] [Related]
14. Granulocyte colony-stimulating factor in glycogen storage disease type 1b. Results of the European Study on Glycogen Storage Disease Type 1.
Visser G; Rake JP; Labrune P; Leonard JV; Moses S; Ullrich K; Wendel U; Groenier KH; Smit GP
Eur J Pediatr; 2002 Oct; 161 Suppl 1():S83-7. PubMed ID: 12373578
[TBL] [Abstract][Full Text] [Related]
15. Current understanding on pathogenesis and effective treatment of glycogen storage disease type Ib with empagliflozin: new insights coming from diabetes for its potential implications in other metabolic disorders.
Maiorana A; Tagliaferri F; Dionisi-Vici C
Front Endocrinol (Lausanne); 2023; 14():1145111. PubMed ID: 37152929
[TBL] [Abstract][Full Text] [Related]
16. Granulocyte colony-stimulating factor corrects the neutropenia associated with glycogen storage disease type Ib.
Wang WC; Crist WM; Ihle JN; Arnold BA; Keating JP
Leukemia; 1991 Apr; 5(4):347-9. PubMed ID: 1709246
[TBL] [Abstract][Full Text] [Related]
17. Granulocyte and granulocyte-macrophage colony-stimulating factors for treatment of neutropenia in glycogen storage disease type Ib.
Schroten H; Roesler J; Breidenbach T; Wendel U; Elsner J; Schweitzer S; Zeidler C; Burdach S; Lohmann-Matthes ML; Wahn V
J Pediatr; 1991 Nov; 119(5):748-54. PubMed ID: 1719175
[TBL] [Abstract][Full Text] [Related]
18. Glycogen storage disease.
Kannourakis G
Semin Hematol; 2002 Apr; 39(2):103-6. PubMed ID: 11957192
[TBL] [Abstract][Full Text] [Related]
19. Neutropenia in glycogen storage disease Ib: outcomes for patients treated with granulocyte colony-stimulating factor.
Dale DC; Bolyard AA; Marrero T; Kelley ML; Makaryan V; Tran E; Leung J; Boxer LA; Kishnani PS; Austin S; Wanner C; Ferrecchia IA; Khalaf D; Maze D; Kurtzberg J; Zeidler C; Welte K; Weinstein DA
Curr Opin Hematol; 2019 Jan; 26(1):16-21. PubMed ID: 30451720
[TBL] [Abstract][Full Text] [Related]
20. Apoptotic neutrophils in the circulation of patients with glycogen storage disease type 1b (GSD1b).
Kuijpers TW; Maianski NA; Tool AT; Smit GP; Rake JP; Roos D; Visser G
Blood; 2003 Jun; 101(12):5021-4. PubMed ID: 12576310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
